Home › Trials › NCT06152575

Evaluating Elranatamab for Relapsed Multiple Myeloma

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

PHASE3 · Pfizer · NCT06152575

This study tests if a new treatment called elranatamab can help people with relapsed multiple myeloma feel better compared to standard therapies they might have already tried.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment492 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer (industry)
Drugs / interventionselranatamab
Locations131 sites (Mobile, Alabama and 130 other locations)
Trial IDNCT06152575 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness of elranatamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), in patients with relapsed multiple myeloma who have previously undergone treatment. Participants will be randomly assigned to receive either elranatamab or a combination of standard therapies selected by the study doctor. The treatment will involve weekly subcutaneous injections of elranatamab, while the combination therapy will include oral medications and injections. The goal is to compare the outcomes of elranatamab against established treatment regimens.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with relapsed multiple myeloma who have received prior treatments including anti-CD38 antibodies and lenalidomide.

Not a fit: Patients with smoldering multiple myeloma or other specific exclusions such as plasma cell leukemia or amyloidosis may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with relapsed multiple myeloma.

How similar studies have performed: Other studies involving bispecific antibodies targeting BCMA have shown promising results, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
* Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
* Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65).
* Have clinical laboratory values within the specified range.
* ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
* Not pregnant or breastfeeding and willing to use contraception.

Exclusion Criteria:

* Smoldering multiple myeloma.
* Plasma cell leukemia.
* Amyloidosis.
* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome.
* Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.
* Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
* Any active, uncontrolled bacterial, fungal, or viral infection.
* Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
* Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy.
* Unable to receive investigator's choice therapy.
* Live attenuated vaccine within 4 weeks of the first dose of study intervention.
* Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study.

Where this trial is running

Mobile, Alabama and 130 other locations

+81 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Multiple Myeloma, Elranatamab, B-Cell Maturation Antigen, BCMA, Bispecific antibody, BCMA-CD3 bispecific antibody, Myeloma, Multiple myeloma

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.